Egis’ website uses cookies to run our website, improve the user experience and monitor the activities. You can customize the use of the cookies by adapting the settings.
Egis World
Egis' products are sold to 100 countries.
Csaba Poroszlai is CEO of Egis Pharmaceuticals PLC
Csaba Poroszlai is confirmed CEO of the company by the Board of Directors of Egis. Balázs Vándor is appointed to the position of the Company’s Chief Financial Officer.
Three Egis Subsidiaries Among the Best Employers
Following the success of Egis Russia and Egis Polska, we are proud to announce that Egis Praha has also been recognized as Best Employer at Aon Hewitt’s Employee Engagement Survey.
Gran Prize - Egis Innovation for Sustainability
Egis has developed a new procedure for the dehalogenation of technological wastewaters. In 2018, the Swedish Chamber of Commerce in Hungary recognized the innovation with the Gran Prize Interdisciplinary Innovative award.
Egis Strengthens European Presence in the Biosimilar Area
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
Other channels
Our mission is to serve people with all of our skills, ensuring that they live a long and healthy life
In the 2022/2023 business year, we spent EUR 48 million on research and development
Our highlighted past and future events you shouldn't miss
Your browser is out of date. Please, use an updated version!